Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.4400 (-1.98%) ($6.3600 - $6.4400) on Fri. Jun. 4, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.5% (three month average) | RSI | 63 | Latest Price | $6.4400(-1.98%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX advances 2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(39%) XBI(38%) ARKK(35%) IBB(32%) IPO(32%) | Factors Impacting HTBX price | HTBX will decline at least -1.75% in a week (0% probabilities). VIXM(-29%) VXX(-22%) UUP(-12%) XLU(-4%) XLP(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.75% (StdDev 3.5%) | Hourly BBV | -1.5 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $6.53(-1.38%) | 10 Day Moving Average | $6.43(0.16%) | 20 Day Moving Average | $6.32(1.9%) | To recent high | -29.6% | To recent low | 10.7% | Market Cap | $709m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |